COR47 Antibody
Description
Clarification of Terminology
CD47 Antibody (often mistaken for "COR47" due to potential typographical errors) is a well-established therapeutic target in oncology. CD47 is a transmembrane protein that inhibits macrophage-mediated phagocytosis by binding to SIRPα on immune cells. Anti-CD47 antibodies block this interaction, enabling immune clearance of cancer cells .
Key Anti-CD47 Antibodies in Development
Below are prominent anti-CD47 antibodies under investigation, supported by clinical and preclinical data:
3.1. CD47-SIRPα Axis Blockade
Anti-CD47 antibodies disrupt the "don’t eat me" signal by preventing CD47-SIRPα interaction, enhancing macrophage phagocytosis of tumor cells . Fc engineering (e.g., GAALIE variant) optimizes binding to activating FcγRs, improving efficacy while reducing toxicity .
3.2. Combination Therapies
-
With Checkpoint Inhibitors: Synergy observed with PD-1/PD-L1 inhibitors via enhanced T-cell activation .
-
With Chemotherapy: Increased tumor cell opsonization improves phagocytosis in AML and MDS .
4.1. Toxicity Profile
-
Hematologic Toxicity: Anemia and thrombocytopenia due to CD47 expression on RBCs and platelets .
-
Mitigation Strategies: IMC-002’s engineered Fc minimizes RBC binding, reducing toxicity .
4.2. Biomarker-Driven Approaches
-
CD47+ Macrophage Density: Correlates with clinical benefit in IMC-002 trials (71.0/mm² vs. 44.3/mm² in non-responders) .
-
FcγR Polymorphisms: Influence antibody efficacy; humanized mouse models aid preclinical optimization .
Future Directions
-
Bispecific Antibodies: IBI322 (CD47/PD-L1) shows promise in relapsed Hodgkin’s lymphoma .
-
Localized Delivery: Intratumoral administration reduces systemic toxicity while enhancing abscopal effects .
-
AI-Driven Biomarkers: Platforms like Lunit SCOPE IO identify responders via macrophage density analysis .
Product Specs
Q&A
FAQs for COR47 Antibody Research (Academic Focus)
Advanced Research Questions
How to resolve contradictions in COR47 localization data across studies?
-
Hypothesis-driven troubleshooting:
-
Assess antibody clonality: Polyclonal vs. monoclonal antibodies may differ in epitope recognition .
-
Evaluate stress conditions: Subcellular shifts may occur depending on stress duration (e.g., acute vs. chronic cold exposure) .
-
Use subcellular fractionation + mass spectrometry to confirm compartment-specific abundance .
-
What strategies optimize COR47 antibody performance in plant tissue-specific profiling?
-
Employ tissue-preferred promoters (e.g., root vascular-specific) in transgenic lines to isolate context-dependent expression .
-
Combine flow cytometry (for single-cell resolution) with RNA-seq to correlate protein and transcript levels .
How to design a study analyzing COR47’s role in nitrogen assimilation under cold stress?
-
Experimental framework:
Data Contradiction Analysis
Conflicting reports on COR47’s role in drought vs. cold adaptation: How to reconcile?
-
Systematic review approach:
-
Stratify studies by stress severity: COR47 may have dual roles depending on stress intensity .
-
Analyze antibody batches: Variability in affinity purification can cause functional discrepancies .
-
Use bimolecular fluorescence complementation (BiFC) to test COR47 interaction partners under differing stress conditions .
-
Can COR47 antibody cross-react with homologs in non-model species?
-
Epitope mapping:
How to assess post-translational modifications (PTMs) of COR47 using antibody-based methods?
-
PTM-specific protocols:
Methodological Innovations
What transient expression systems improve COR47 antibody validation throughput?
How to integrate COR47 antibody data with multi-omics datasets?
-
Workflow:
